References
- Bille J, Marchetti 0, Calandra T. Chancing face of health-care associated fungal infections. Curr Opin Infect Dis 2005; 18: 314–319.
- Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002; 15: 569–574.
- Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis 2005; 41: 521–526.
- Denning DW, Radford SA, Oakley KL, Johnson EM, WarnockDW. Correlation between in vitro susceptibility testing to itraconazole and in vivo clinical outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40: 401–414.
- Ghannoum MA, Rex JR, Galgiani JN. Susceptibility test-ing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol 1996; 34: 489–495.
- Espinel-Ingroff A. Utility of mould susceptibility testing. Curr Opin Infect Dis 2003; 16: 527–532.
- Pfaller MA, Messe SAr, Hollis RJ, Jones RN, The Sentry Participants Group. Antifungal activity of posocona-zole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother 2002; 46: 1032–1037.
- Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40–79.
- Jeu LA, Piacenti FC, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin Ther 2003; 25: 1321–1381.
- National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: Approved Standard, M38-A. 2002; NCCLS, Wayne, PA.
- Castro C, Serrano MC, Flores B, Espinel-Ingroff A, Martin-Mazuelos E. Comparison of the Sensititre YeastOne colorimetric antifungal panel with a modified NCCLS M38-A method to determine the activity of voriconazole against clini-cal isolates of Aspergillus species. J Clin Microbiol 2004; 42: 4358–4360.
- Drago M, Scaltrito MM, Cariani L, Morace G. In vitro testing of Aspergillus fumigatus clinical isolates for suscepti-bility to voriconazole, amphotericin B and itraconazole: com-parison of Sensititre versus NCCLS M38-A using two different inocula. J Chemother 2004; 16: 474–478.
- Espinel-Ingroff A, Bartlett M et al. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp: NCCLS collaborative evaluation. Antimicrob Agents Chemother 2001; 45: 1828–1835.
- Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142–1151.